AI-assisted summary

Sarasota Memorial Hospital is part of a clinical trial for a drug that may reduce heart attacks in patients with a specific genetic variant.

The investigational drug, dalcetrapib, is being studied for its effect on individuals with the ADCY9 AA genotype following a cardiac event.

Eligible participants must be over 45 and have been recently hospitalized for a sudden cardiac event.

The national trial aims to enroll 2,000 people, with half receiving the drug and half receiving a placebo.

Sarasota Memorial Hospital is enrolling eligible patients in a clinical trial of an investigational drug that could reduce heart attacks and mortality in individuals with a specific genetic variant following a sudden cardiac event.

The research study for the clinical trial offered b

See Full Page